CTLA4 and neuroblastoma: Previous studies from our laboratory revealed that a neuroblastoma vaccine approach incorporating BET/JQ1-treated cancer cells, along with anti-CTLA4 and anti-PDL-1 checkpoint inhibitors, resulted in potent anti-tumor immunity but also induced autoimmune responses and immune cell infiltration, most notably in cardiac tissue (35, 36).